02/20/2026
🚨 A major lawsuit just escalated pressure on compounded GLP-1s in Med Spas
Last week, Novo Nordisk filed suit against telehealth company Hims & Hers over compounded semaglutide products, signaling intensifying legal and regulatory scrutiny around how weight-loss medications are sourced and marketed.
For Med Spas offering compounded GLP-1 therapies, this is a signal that as demand for weight-loss injections grows, so does attention on:
✔️ prescribing oversight and documentation
✔️ pharmacy sourcing relationships
✔️ representations of FDA approval or “equivalence”
✔️ marketing language tied to brand-name drugs
When high-profile litigation enters the space, scrutiny tends to expands.
Compounded medications can play a role in patient care, but how they’re sourced, described, and documented matters more than ever.
💡 Follow Spakinect for compliance insights tailored specifically to Med Spa owners navigating evolving regulatory pressure.
To read more on the lawsuit, visit: https://www.cnbc.com/2026/02/09/novo-nordisk-sues-hims-hers-compounded-obesity-drugs.html